United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - mitomycin - powder and solvent for intravesical solution - 40mg

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Israel - English - Ministry of Health

j-c health care ltd - doxorubicin hydrochloride - liposome concentrate for solution for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Israel - English - Ministry of Health

medison pharma ltd - doxorubicin hydrochloride - powder,dispersion and solvent for concentrate for dispersion for infusion - doxorubicin hydrochloride 50 mg vials - doxorubicin - doxorubicin - myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - idarubicin hydrochloride - powder for concentrate for solution for infusion - idarubicin hydrochloride 10 mg/vial - idarubicin - idarubicin - antimitotic and cytotoxic agent. acute non-limphocytic leukemia (anll) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.acute limphocytic leukemia (all) as second line treatment in adults and children.

Israel - English - Ministry of Health

novartis israel ltd - mitoxantrone as hydrochloride - concentrate for solution for infusion - mitoxantrone as hydrochloride 2 mg/ml - mitoxantrone - mitoxantrone - treatment of advanced breast cancer, non-hodgkin's lymphomas, acute non lymphocytic leukemia palliation of non resectable primary hepatocellular carcinoma. mitoxantrone in combination with corticosterolds is indicated for inital chemotherapy in patients with pain due to advanced hormone-refractory prostate cancer. for reduction of neurologic disability and/or frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remmitting multiple sclerosis (patients whose neurologic status is significantly abnormal between relapses), for patients 18-55 years old.בקשה לשינוי התוויה: 5/1/2021mitoxantrone is indicated in the treatment of metastatic breast cancer.mitoxantrone is indicated in the treatment of non-hodgkin’s lymphoma.mitoxantrone is indicated for the treatment of acute myeloid leukaemia (aml) in adults.mitoxantrone in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia.mitoxantrone is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.mitoxantrone is indicated for treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist.